Ubs Group Ag Intra Cellular Therapies, Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ITCI
# of Institutions
378Shares Held
84.7MCall Options Held
319KPut Options Held
143K-
Vanguard Group Inc Valley Forge, PA9.63MShares$832 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$546 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.29MShares$457 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.85MShares$333 Million1.4% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.05MShares$264 Million3.36% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $8.16B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...